Open AccessA Phase I Study of Cabozantinib (XL184) in Patients with Differentiated Thyroid Cancer
Author(s) -
Maria E. Cabanillas,
Marcia S. Brose,
Jaymes Holland,
Kimberly Ferguson,
Steven I. Sherman
Publication year - 2014
Publication title -
thyroid
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.918
H-Index - 142
eISSN - 1557-9077
pISSN - 1050-7256
DOI - 10.1089/thy.2014.0125
Subject(s) - cabozantinib , medicine , tolerability , response evaluation criteria in solid tumors , medullary thyroid cancer , adverse effect , oncology , concomitant , cancer , thyroid cancer , tyrosine kinase inhibitor , phases of clinical research , surgery , clinical trial
Cabozantinib targets tyrosine kinases including MET, vascular endothelial growth factor (VEGF) receptor 2, and rearranged during transfection (RET). Differentiated thyroid cancer (DTC) is a tumor type that may be sensitive to cabozantinib. Therefore, we evaluated cabozantinib in a cohort of heavily pretreated patients with metastatic DTC.